Physician profile
Daniel G Orr
NPI 1891846614
$39,351.87
in general payments reported to CMS, 2019-2025
39 companies · $2,192 in 2025
The $2,192 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,851 · 2020: $6,842 · 2021: $7,774 · 2022: $6,980 · 2023: $8,492 · 2024: $2,220 · 2025: $2,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,132 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,475 · Travel and Lodging: $1,286 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,131.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,475.00 |
| Travel and Lodging | $1,285.61 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,289.82 | 2021-2025 | |
| Allergan, INC. | $10,777.03 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $3,948.74 | 2019-2024 | Jornay Pm |
| Lilly USA, LLC | $1,671.55 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,027.71 | 2021-2025 | Caplyta |
| Corium, LLC | $838.64 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $825.56 | 2021-2023 | Qelbree |
| Novo Nordisk INC | $811.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $698.76 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $665.02 | 2019-2025 | Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $542.61 | 2019-2025 | Rexulti, Nuedexta |
| Pfizer INC. | $510.75 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $500.00 | 2020-2025 | Ingrezza |
| Lundbeck LLC | $497.50 | 2020-2025 | Rexulti |
| Axsome Therapeutics, INC. | $365.94 | 2023-2025 | Auvelity, Sunosi |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.